Accuray (ARAY) Expected to Announce Quarterly Earnings on Wednesday

Accuray (NASDAQ:ARAY) is expected to announce its Q2 2026 results after the market closes on Wednesday, February 4th. Analysts expect the company to announce earnings of ($0.11) per share and revenue of $100.86 million for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, February 4, 2026 at 4:30 PM ET.

Accuray (NASDAQ:ARAY) last posted its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.13). Accuray had a negative return on equity of 34.06% and a negative net margin of 4.28%.The firm had revenue of $93.94 million for the quarter, compared to analysts’ expectations of $91.34 million. On average, analysts expect Accuray to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Accuray Price Performance

Accuray stock opened at $0.81 on Monday. The company has a fifty day simple moving average of $0.91 and a 200-day simple moving average of $1.28. The firm has a market capitalization of $91.50 million, a price-to-earnings ratio of -5.05 and a beta of 1.15. The company has a quick ratio of 0.76, a current ratio of 1.56 and a debt-to-equity ratio of 2.06. Accuray has a 52-week low of $0.78 and a 52-week high of $2.95.

Institutional Investors Weigh In On Accuray

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ARAY. Vanguard Group Inc. lifted its stake in shares of Accuray by 2.0% in the 3rd quarter. Vanguard Group Inc. now owns 5,476,677 shares of the medical equipment provider’s stock valued at $9,146,000 after purchasing an additional 106,087 shares during the last quarter. Armistice Capital LLC increased its position in shares of Accuray by 2.7% during the 3rd quarter. Armistice Capital LLC now owns 3,324,000 shares of the medical equipment provider’s stock worth $5,551,000 after purchasing an additional 88,000 shares during the last quarter. Geode Capital Management LLC raised its holdings in Accuray by 7.8% in the 2nd quarter. Geode Capital Management LLC now owns 2,421,724 shares of the medical equipment provider’s stock valued at $3,318,000 after buying an additional 174,703 shares during the period. TENOR CAPITAL MANAGEMENT Co. L.P. acquired a new position in Accuray in the second quarter valued at about $2,055,000. Finally, Citadel Advisors LLC boosted its stake in Accuray by 9,301.4% during the third quarter. Citadel Advisors LLC now owns 662,499 shares of the medical equipment provider’s stock worth $1,106,000 after buying an additional 669,699 shares during the period. Institutional investors and hedge funds own 64.08% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. Wall Street Zen raised shares of Accuray from a “sell” rating to a “hold” rating in a research note on Monday, January 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Accuray in a research report on Monday, December 29th. Finally, BTIG Research reduced their price objective on Accuray from $5.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday, November 6th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $4.00.

About Accuray

Accuray Incorporated (NASDAQ: ARAY) is a global medical device company that develops, manufactures and markets innovative radiation therapy solutions for the treatment of cancer. The company’s flagship products include the CyberKnife® System, a robotic radiosurgery platform offering sub-millimeter precision, and the TomoTherapy® System, which combines helical computed tomography (CT) imaging with intensity-modulated radiation therapy (IMRT). More recently, Accuray introduced the Radixact® System, an advanced iteration of its TomoTherapy technology designed to enhance treatment speed and clinical workflow.

Accuray’s suite of products enables clinicians to deliver highly targeted radiation doses while minimizing exposure to surrounding healthy tissue.